Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study

Recruiting now · Not applicable

Conditions studied: Postpartum Preeclampsia

In brief

The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.

Key facts

Study ID

NCT07185204

Run by

Medical College of Wisconsin

People needed

60

Starts

2026-03-03

Expected to finish

2027-06-01

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
• Age ≥ 18 years
• Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital
• At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF
• 1 or more high risk factors:
• History of preeclampsia
• Type 1 or 2 diabetes
• Multifetal gestation?
• Renal disease
• Autoimmune disease
• 2 or more moderate risk factors:
• Nulliparity
• BMI > 30
• First-degree relative with a history of preeclampsia
• African American race
• Low socioeconomic status
• Age > 35 years
• History of low birthweight or small for gestational age
• Previous adverse pregnancy outcome
• Interpregnancy interval > 10 years

You may not qualify if…

• Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
• Chronic hypertension, according to ACOG guidelines
• Known allergy or contraindication to nifedipine
• Inability or unwillingness to provide informed consent
• Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)

Where it is running

• Dhulikhel Hospital — Dhulikhel, Nepal (enrolling)
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.